{"id":"rifamycin-sv-mmx","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rifamycin SV is an ansamycin antibiotic that binds to bacterial RNA polymerase and blocks transcription. The MMX (Multi-Matrix system) formulation is an oral delivery technology designed to release the drug specifically in the colon, allowing high local concentrations while minimizing systemic absorption. This targeted approach is intended to treat gastrointestinal infections while reducing systemic side effects.","oneSentence":"Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:15.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (CDI)"},{"name":"Traveler's diarrhea"}]},"trialDetails":[{"nctId":"NCT04082780","phase":"PHASE2","title":"Rifamycin in Minimal Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2019-09-01","conditions":"Hepatic Encephalopathy, Cirrhosis, Liver","enrollment":30},{"nctId":"NCT04027894","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years","status":"UNKNOWN","sponsor":"RedHill Biopharma Limited","startDate":"2024-01","conditions":"Traveler's Diarrhea","enrollment":142},{"nctId":"NCT04026984","phase":"PHASE2","title":"Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years","status":"UNKNOWN","sponsor":"RedHill Biopharma Limited","startDate":"2024-06","conditions":"Traveler's Diarrhea","enrollment":142},{"nctId":"NCT04501380","phase":"PHASE2","title":"Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)","status":"UNKNOWN","sponsor":"Bradley Connor","startDate":"2020-06-30","conditions":"Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection","enrollment":30},{"nctId":"NCT03099785","phase":"PHASE2","title":"Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D","status":"COMPLETED","sponsor":"Cosmo Technologies Ltd","startDate":"2017-12-18","conditions":"Diarrhea-predominant Irritable Bowel Syndrome","enrollment":279},{"nctId":"NCT03447821","phase":"PHASE2","title":"Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea","status":"COMPLETED","sponsor":"Cosmo Technologies Ltd","startDate":"2008-02","conditions":"Infectious Diarrhoea","enrollment":40},{"nctId":"NCT01208922","phase":"PHASE3","title":"Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2010-11","conditions":"Traveler's Diarrhea","enrollment":835},{"nctId":"NCT01142089","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)","status":"COMPLETED","sponsor":"Cosmo Technologies Ltd","startDate":"2010-05-27","conditions":"Traveler's Diarrhea","enrollment":264},{"nctId":"NCT02969252","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Cosmo Technologies Ltd","startDate":"2015-07","conditions":"Healthy","enrollment":18},{"nctId":"NCT01847664","phase":"PHASE2","title":"Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2013-08","conditions":"Uncomplicated Diverticulitis","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rifamycin","Aemcolo"],"phase":"phase_3","status":"active","brandName":"Rifamycin SV MMX","genericName":"Rifamycin SV MMX","companyName":"RedHill Biopharma Limited","companyId":"redhill-biopharma-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon. Used for Clostridioides difficile infection (CDI), Traveler's diarrhea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}